Change Password!
Reset Password!
Choosing Deucravacitinib over Apremilast can potentially lead to better and sustained outcomes in treating moderate to severe psoriasis.
According to a recent research in 'Dermatology and Therapy' aimed to compare the overall 52-week benefits of starting treatment with Deucravacitinib (tyrosine kinase 2 inhibitor) versus Apremilast. It also examined whether starting and continuing Deucravacitinib throughout 52 weeks provided greater benefits compared to starting with Apremilast and switching to Deucravacitinib at week 24.
April W. Armstrong et al. executed a post hoc analysis of POETYK PSO-1 trial, comparing the efficacy of Deucravacitinib 6 mg given one time daily and Apremilast 30 mg given two times daily in people with moderate to severe plaque psoriasis. Patients who failed to reach a 50% decrease in their Psoriasis Area and Severity Index (PASI 50) after 24 weeks of treatment with Apremilast were transitioned to Deucravacitinib. They estimated the overall advantages of Deucravacitinib versus Apremilast over 52 weeks based on the percentage of patients attaining at least a 75% improvement in PASI score (PASI 75) and the proportion with a Physician Global Assessment score of 0 or 1 (clear or almost clear skin).
Overall, 332 patients who started treatment with Deucravacitinib experienced a 50% higher improvement based on PASI 75 and a 58% higher improvement based on sPGA 0/1 scores compared to 168 patients who started Apremilast (N = 168) over 52 weeks.
The findings from this analysis support the primary efficacy analysis, affirming that Deucravacitinib is more effective than Apremilast in treating moderate to severe plaque psoriasis, regardless of whether patients had previously used systemic or biologic treatments.
Dermatology and Therapy
Cumulative Benefit Over 52 Weeks with Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis
April W. Armstrong et al.
Comments (0)